Brazil's drug regulator has cleared Dr Reddy's to sell a generic semaglutide, reversing an April rejection and adding a large Indian manufacturer to a market Novo Nordisk once supplied alone.
What Happened
On Thursday, 5 November 2026, Dr Reddy's Laboratories said Brazil's National Health Surveillance Agency, ANVISA, had granted marketing authorisation for its generic semaglutide — the molecule Novo Nordisk sells as Ozempic and Wegovy. The clearance covers adults whose type 2 diabetes is not sufficiently controlled, used alongside diet and exercise, in a pre-filled injector pen.
The decision reverses an April 2026 refusal, when ANVISA concluded the application did not satisfy all regulatory requirements. Dr Reddy's is not Brazil's first generic entrant: an EMS pen was approved after the patent lapsed, and a Sandoz product developed with Adalvo was cleared in late July. The significance of Thursday's approval is not novelty but depth — a large Indian manufacturer joining a price contest in a market that was, until this year, single-supplier.
Dr Reddy's has made semaglutide central to its growth story. It sells a generic in India under its own brand and has told investors it is targeting launches across Latin America and Africa in the coming months. It also plans to relaunch in Canada this quarter, after recalling batches there earlier in 2026 when testing found an impurity in the active ingredient.
Who Is Affected
- Patients in Brazil — the company cites 16.6 million adults aged 20 to 79 living with diabetes, the sixth-largest such population in the world.
- Novo Nordisk — losing exclusivity market by market while still defending brand pricing where patents hold.
- Generic manufacturers and exporters — a Brazilian approval becomes a reference point for filings elsewhere in Latin America.
- Compounding pharmacies and research buyers — more legal API sources mean more supplier claims to verify.
- Customs and regulators — every legitimate supply chain creates a template counterfeiters can imitate.
Timeline
- March 2026 — semaglutide patents expire in Brazil and India; generic launches follow within days.
- April 2026 — ANVISA rejects Dr Reddy's application as not meeting all requirements.
- July 2026 — a Sandoz and Adalvo generic semaglutide is approved in Brazil.
- October 2026 — Dr Reddy's recalls Canadian batches over an API impurity and rolls out replacement brands amid an Indian supply disruption.
- 5 November 2026 — ANVISA grants Dr Reddy's marketing authorisation.
- Coming months — Latin America and Africa launches, with a Canadian relaunch targeted this quarter.
What This Means for Researchers
A legal multi-source market changes the verification problem rather than solving it. When one manufacturer supplies a molecule, a certificate of analysis is close to a formality; when three or four do, batch-level documents become the only way to know which material you are actually holding. The Canadian recall is the useful precedent: the impurity was identified in the active ingredient, not in the finished pen, so inspecting a finished product would not have caught it.
Regulatory approval also says nothing about research-grade material. A marketing authorisation is granted for a named manufacturer, a named facility and a specific clinical indication. It does not transfer to a lyophilised vial sold through an unregulated channel, and it does not mean a seller citing "ANVISA-approved" is describing the product in the box.
How to Verify Your Peptides
Independent testing is the only check that travels across borders. Our guides explain what a legitimate panel should include: how testing works, HPLC versus LC-MS, and identity, purity and fill weight.
Safe Alternatives
For background on the molecule itself, see our semaglutide peptide page. Buyers comparing suppliers can review vetted listings in the vendor directory.
Sources
Industry reports; regulatory announcements from Brazil's National Health Surveillance Agency; company disclosures.